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During a 10 year study period 234 patients were admitted on 371 occasions with a total of 566 acute variceal
bleeding episodes. Of these, 173 patients had 343 variceal bleeds which required balloon tamponade to
achieve initial control of bleeding during 229 admissions and were then referred for emergency injection
sclerotherapy. Sixty-eight percent of these patients had alcoholic cirrhosis and 42% were poor risk Grade
C patients. Injection sclerotherapy was performed initially using the rigid Negus oesophagoscope under
general anaesthesia and later using the fibreoptic endoscope under light sedation. Definitive control of
variceal bleeding was achieved with sclerotherapy during 197 hospital admissions (92%). Of the 17
failures of emergency sclerotherapy, 4 patients died from uncontrolled bleeding and 13 patients
underwent major surgical intervention. Definitive control of variceal bleeding was achieved with a single
injection treatment in 138 hospital admissions (70%). Complications were mostly of a minor nature and
occurred at a rate of6% per injection treatment. The overall hospital admission mortality was 36%. The
majority of patients died due to liver failure. The mortality in patients who required 4 injection treatments
to control variceal bleeding was 71%. Injection sclerotherapy is proposed as the emergency treatment of
choice for patients whose variceal bleeding continues or recurs after initial conservative management.
Patients whose variceal bleeding is not controlled by 2 injection treatments require more major
emergency surgery.
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INTRODUCTION
Emergency injection sclerotherapy has become firmly established as part of the
management of acute variceal haemorrhage, particularly if bleeding does not
respond to simple conservative measures1-3. Definitive control of variceal
haemorrhage with this form of therapy is reported to be in excess of 90%4-9. This
paper reviews the first 10 years of our prospective study of injection sclerotherapy in
the emergency management of the subset of bad-risk patients with endoscopically
proven active variceal haemorrhage who required Sengstaken balloon tube
tamponade for initial control of bleeding. During the 10 years technical variations of
sclerotherapy were evaluated and a new technique introduced after 5 years.
*Correspondence to: Professor John Terblanche, Department of Surgery, University of Cape Town
Medical School, Observatory 7925, South Africa.
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PATIENTS AND METHODS
Patients
All 306 patients admitted to the adult wards of the hospital with endoscopically
proven oesophageal variceal bleeding during the 10 year period August 1975 to
August 1985 were evaluated and documented prospectively on computer pro forma
sheets. Of these, 234 patients were referred specifically for emergency management
of actively bleeding varices. These latter patients were admitted on 371 occasions
with a total of 566 acute variceal bleeding episodes (Figure 1). In 223 of the 566 acute
bleeding episodes, bleeding stopped after the initial conservative treatment and
further emergency therapy was not required. Patients who had either continued
variceal bleeding despite the initial conservative therapy or massive variceal
bleeding, were treated with immediate tamponade with a Sengstaken-Blakemore
balloon tube and were later subjected to emergency injection sclerotherapy. Only
this latter group of 173 patients with continued active variceal bleeding on their first
or subsequent admission have been included in the present study which evaluated
emergency treatment of continued variceal bleeding.
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566 variceal bleeds
INTRAVENOUS FLUIDS
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Continued bleeding
173 patients
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Figure I Treatment and outcome of patients with actively bleeding oesophageal varices.EMERGENCY SCLEROTHERAPY FOR VARICEAL BLEEDING 209
The subgroups of patients included in the controlled trials all gave informed
consent and the trials were approved by the Faculty ofMedicine Ethics and Research
Committee.
The 173 patients included in this evaluation of emergency sclerotherapy had 343
acute variceal bleeds which were treated with balloon tamponade in 229 admissions
during the 10 year analysis period (Figure 1). There were 125 males and 48 females
and the mean age was 47.8 + 1.26 years (range 13-80). A modified Pugh-Child’s risk
Grade was used to assess the severity of the liver disease10. On admission 34 patients
were Grade A, 60 were Grade B and 67 were Grade C. The risk grade could not be
determined in 12 patients. The aetiology of the portal hypertension is shown in Table
I. Histological evidence of cirrhosis was found in 139 patients, and of these 116
patients had a definite history of alcohol abuse. A diagnosis of extrahepatic portal
venous obstruction was based on normal liver histology and/or algiographic
findings.
Initial management of the acute variceal bleeding episode
Patients with suspected acute oesophageal variceal bleeding were admitted,
whenever possible, to an intensive care or high care unit. Initial management
included resuscitation with crystalloids and blood, and medication to combat
encephalopathy. Most patients received intravenous vasopressin prior to emergency
endoscopy. During the first two years bolus doses of vasopressin were used, but
since then it has been infused continuously intravenously (0.4 units per minute)9.
Patients who did not have varices and those with varices but who were bleeding from
other lesions were excluded from the study. In patients with varices that had stopped
bleeding, the vasopressin infusion was continued for 24-48 hours. A Sengstaken-
Blakemore balloon tube was only inserted in those patients with active variceal
bleeding at the time of emergency endoscopy. This latter group of patients
underwent emergency injection sclerotherapy between 6 and 24 hours after inserting
the Sengstaken tube. These 173 patients constitute the present study groups (Figure
1). Resuscitation was continued and liver failure treated with Neomycin and/or
Lactulose as required.
Injection Sclerotherapy Techniques
During the 10-year study period mainly 2 sclerotherapy techniques were used, with
either a rigid or a flexible endoscope. The technique of emergency injection
sclerotherapy using the rigid Negus oesophagoscope has been described in detail
elsewere6’1r. A standard anaesthetic technique was usedla. After removing the
Table 1 Aetiology of the portal hypertension.
Alcoholic cirrhosis 116
Cryptogenic cirrhosis 23
Portal vein thrombosis 18
Chronic active hepatitis 5
Other 3
Unknown 8
TOTAL 173210 D. KAHN, P.C. BORNMAN and J. TERBLANCHE
Sengstaken tube, a 50cm rigid Negus oesophagoscope, modified with a slot19, was
passed to the oesophagogastric junction and the sclerosant, ethanolamine oleate,
injected directly into the varix. In most cases three variceal channels presented for
injection and on any one occasion a total of between 6 and 20 ml of sclerosant was
injected per treatment session. The oesophagoscope was left in situ for a further 5
minutes to compress the varices. In the first 2 years of the study a Sengstaken tube
was often inserted following sclerotherapy but was avoided thereafter because of the
associated dangers9.
Fibrooptic endoscopic injection sclerotherapy has been used increasingly in recent
patients, some of whom were included in a controlled trial comparing the two
techniques13. Fibreoptic sclerotherapy was used almost exclusively in the latter 5
year period. Fibreoptic sclerotherapy was performed under light sedation using an
unmodified endoscope. The sclerosant, ethanolamine oleate, was injected both
intra- and paravariceally and a total of between 5 and 20 ml of sclerosant was injected
during any one treatment sessionTM. In 1984, for four months, during and after a visit
by Paquet, a few patients were injected using his paravariceal technique
15 with
aethoxysclerol as the sclerosing agent.
RESULTS
Control ofBleeding
A Sengstaken-Blakemore balloon tube was inserted for initial control of 343 variceal
bleeding episodes during 229 admissions. In 15 patients the Sengstaken tube
controlled the bleeding but the patients died before undergoing sclerotherapy. Initial
balloon tamponade followed by emergency injection sclerotherapy failed to control
bleeding in 17 admissions. Definitive control of variceal bleeding was achieved with
sclerotherapy during the hospitalisation period in 197 admissions (92%). Of the 17
failures of tamponade and sclerotherapy, 4 patients died from uncontrolled bleeding
and 13 patients required emergency surgical intervention in the form of a
devascularisation procedure in 10 patients, a portacaval shunt in 2 patients and a
distal splenorenal shunt in 1. The variceal bleeding ceased post-operatively in all the
cases treated surgically but 8 patients (61%) died from causes other than variceal
bleeding. In 2 of the 4 patients who died from uncontrolled bleeding, the bleeding
continued with the Sengstaken tube in place. These are the only 2 patients in whom
the balloon tube failed to achieve temporary control of variceal bleeding. Fifty-six
patients died during the hospitalisation period after definitive control of the variceal
bleeding was achieved.
Definitive control of variceal bleeding was achieved with a single injection
treatment in 70% of hospital admissions (138 admissions). Two injection treatments
were required for definitive control on 40 occasions and 3 or 4 injection treatments
on 16 and 4 occasions respectively.
Complications
A detailed evaluation of our overall experience ofthe complications of sclerotherapy
is presented elsewhere16. These complications were mostly of a minor nature. During
the 10-year period the 173 patients under evaluation for acute variceal bleedingEMERGENCY SCLEROTHERAPY FOR VARICEAL BLEEDING 211
Table 2 Outcome after initial balloon tamponade control of bleeding.
Definitive control of bleeding
Died before sclerotherapy
Failed sclerotherapy:
Died from uncontrolled bleeding
Required surgical intervention
TOTAL
Hospital Admissions
197
15
4
13
229
received a total of 311 emergency injection sclerotherapy treatments. There
were 19 major oesophageal complications; the morbidity per injection was there-
fore 6.1%. No frank oesophageal perforations were associated with emergency
sclerotherapy.
An injection site leak, as described previously9, represents a localised,
perioesophageal leak and is demonstrated on barium or gastrografin swallon. It
occurred after emergency injection sclerotherapy in 14 patients. This complication
was suspected in patients with persistant pain and pyrexia after sclerotherapy and the
diagnosis was confirmed on gastrografin swallow. All patients settled on conservative
treatment which included nil by mouth, intravenous fluids, hyperalimentation (when
indicated) and antibiotics. Subsequent sclerotherapy was delayed and there was an
associated mortality16.
Mild oesophageal stenosis demonstrated by barium swallow occurred in 5
patients. These patients complained of dysphagia following sclerotherapy. In all the
patients it was a transient phenomenon and none ofthe patients required dilatation.
Superficial mucosal slough was noted on subsequent endoscopy in a number of
patients, and at times resulted in repeated long-term sclerotherapy being delayed.
One patient continued to bleed from the mucosal slough and required a
devascularisation procedure; he eventually died from multiorgan failure.
Mortality (Tables 3 and 4)
Eighty-three of the 173 patients who required balloon tamponade for initial control
of variceal haemorrhage died during the 229 hospital admissions. Overall hospital
admission mortality in this difficult to treat subset of patients with continued active
variceal bleeding was therefore 36%. However 15 patients died while temporarily
controlled with the Sengstaken-Blakemore tube in situ before receiving
sclerotherapy. Thus the hospital admission mortality after acute injection
sclerotherapy was 32%. Eight patients died after various surgical procedures from
causes other than variceal bleeding. Only 4 patients (2.3%) died from uncontrolled
variceal bleeding. Thirty-eight of the hospital deaths after sclerotherapy were
modified Pugh-Child’s Grade C at the initial assessment, 27 were Grade B and 3 were
Grade A. The latter 3 patients, although Grade A at their initial assessment had all
deteriorated to modified Pugh-Child’s Grade B during the admission for the massive
variceal bleed which preceeded their death.
Patients who only required a single injection sclerotherapy treatment had
a mortality of 22% whereas the mortality was 71 when 4 injections were needed
(Table 3).212 D. KAHN, P.C. BORNMAN and J. TERBLANCHE
Table 3 Mortality related to number of injection sclerotherapy treatments undertaken.
Number ofAdmissions Deaths Mortality
1 Injection Treatment 143 31 22%
2 Injection Treatments 48 25 52%
3 Injection Treatments 16 7 44%
4 Injection Treatments 7 5 71%
TOTAL 214 68
The causes of death are shown in Table 4. The majority of patients died of liver
failure. In 32 patients the liver failure was associated with multiorgan failure. Only
4 patients (2.3%) died as a result of uncontrolled bleeding.
Table 4 Causes of death.
Patients
Liver Failure:
Primary 33
Associated Multiorgan Failure 32
Cardiorespiratory 12
Bleeding 4
Sepsis 2
TOTAL 83
DISCUSSION
The use of injection sclerotherapy for oesophageal varices was first described by
17 Crafford and Frenckner in 1939 Their report of the elective treatment of a single
patient who had previously bled from oesophageal varices, stimulated considerable
interest. However isolated favourable reports were overshadowed by the advent and
widespread adoption of portacaval shunting at that time. In 1973 Johnston and
Rodgers
4 reported excellent results with injection sclerotherapy for acute variceal
bleeding. This was followed in 1979 by the inital report on emergency sclerotherapy
from our group
6 and thereafter interest in sclerotherapy as an alternative to surgery
was revived. Since then injection sclerotherapy has become firmly established as the
treatment of choice in the emergency management of bleeding oesophageal varices.
Three controlled trials have shown injection sclerotherapy to be superior to
conventional treatment, including balloon tamponade, in the emergency
management of acute variceal bleeding1-3. Alternative therapeutic modalities in the
management of bleeding oesophageal varices, including percutaneous transhepatic
18 19 21 obliteration emergency_ portosystemic shunting and devascularisation and
22 24 transection procedures have been associated with a signficant morbidity and
mortality and, other than with shunting, a high rate of rebleeding. A recent
controlled trial has rekindled interest in portacaval shunting in poor risk patients25.
This paper reports a 10-year prospective evaluation of emergency injection
sclerotherapy in patients with acute bleeding oesophageal varices who required a
Sengstaken tube for initial control of haemorrhage. Most of the survivors went on toEMERGENCY SCLEROTHERAPY FOR VARICEAL BLEEDING 213
have repeated sclerotherapy as part of their long-term management, which will be
our hospital in August 1975 because of the disappointing high morbidity and
mortality reported with conservative measures, including our own experience of the
use of the Sengstaken tube alone26, and both our experience and the reported
experience with operative procedures, such as direct operations on the varices22’23
and emergency portacaval shuntinga9.
In the present study of emergency management, definitive control of variceal
bleeding was achieved in 92% of hospital admissions where balloon tube tamponade
was followed by emergency sclerotherapy and usually only a single injection
treatment was required (70%). Johnston and Rodgers4, Paquet and Oberhammer5,
6.-9 27 Terblanche et al’, and Spence et al have also reported control rates of over 90
percent. The present results, with more patients, confirm our earlier publications6’9
showing the superiority of combined sclerotherapy and balloon tamponade when
compared with the use of the Sengstaken tube alone, where the rate of rebleeding
after removal of the tube was 60% in our experience 26.
The total hospital admission mortality rate for sclerotherapy treated patients was
32%, which compares favourably with the mortality rate of 60% in patients
previously treated with a Sengstaken tube only26. The mortality rates in other studies
of sclerotherapy have varied between 14 and 280//04-6’9’27, and depended on the status
of the liver function of the patients included. These mortality rates compare
favourably with that achieved after any operative procedure in these very ill patients.
The majority of our patients were alcoholic cirrhotics with severely compromised
liver function and liver failure was the major cause of death. Only 4 patients died
from uncontrolled bleeding. It is important to note that in many patients the liver
failure was preceeded by a variceal bleed and thus the actual categorisation of the
cause of death remains difficult.
In this study patients who received four injection treatments had an unacceptably
high mortality. In an earlier study we reported a mortality rate of 69% in patients
who received three or four injection treatments with a mortality of nearly 90% if
good risk modified Pugh-Child’s A Grade patients are excluded28. The present
findings support our previous recommendation that those patients who continue to
bleed from varices after two injection treatments should have a balloon tube
reinserted and be considered for other treatment modalities. The surgical options
23 24 recommended in these high risk patients are a transection procedure or a
portacaval shunt20’21’25’29.
Which injection sclerotherapy technique is best, remains unresolved. In the
present study varices were injected either with the modified rigid Negus
oesophagoscope under general anaesthetic and the sclerosant injected
intravascularly into the varix, or with the flexible endoscope under light sedation and
the sclerosant injected using a combined intra- and paravariceal iniection
techniqueTM. These two techniques were compared in a group of 70 patierts in a
randomised controlled trial and were found to be equally effective in controlling
13- acute variceal bleeding and in the long term eradication of oesoophageal varices
Although the modified rigid oesophagoscope may be more efficient in controlling
recurrent active acute bleeding from varices in some difficult patients, because of the
more controlled situation under anaesthesia with endotracheal intubation, we would
only recommend the use of a rigid endoscope if considerable expertise is available.
Where a flexible endoscope technique is used, we currently protect the airway with
an endotracheal tube in all stuperose or comatose patients. A paravariceal technique214 D. KAHN, P.C. BORNMAN and J. TERBLANCHE
with the flexible oesophagoscope has also been shown by others to be highly
effective2’s’as. Further controlled trials are required to determine the best technique
and the best sclerosant.
Since the present 10 year evaluation closed we have been evaluating sclerotherapy
treatment at the time of the first diagnostic endoscopy, whenever practical. Although
this approach appears logical there is currently no controlled trial data to support its
use. For the failures of sclerotherapy we advocate simple staple gun transection of
the oesophagus, but portacaval shunting requires re-evaluation in the light of the
satisfactory results reported by Cello et al in their trial comparing it with
25 sclerotherapy in poor risk patients and the data from two other recent Californian
studies2a,29.
In conclusion, we believe that emergency injection sclerotherapy is the treatment
of choice for patients in whom variceal bleeding continues or recurs following initial
conservative treatment and who require balloon tamponade for initial control of
bleeding. The role of immediate sclerotherapy at the time of the first diagnostic
endoscopy remains to be established. The failures, defined as those patients not
controlled by i or 2 injection sclerotherapy treatments, should be subjected to more
major surgery. Here the choice between a shunt and a transection operation also
remains to be defined by controlled trials.
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INVITED COMMENTARY
This is an important ten year audit of the emergency management ofbleeding varices
from a centre which did much to establish the worth of this technique. These
excellent results support my long held belief that injection sclerotherapy is the216 D. KAHN, P.C. BORNMAN and J. TERBLANCHE
"best buy" for the acute bleeding episode. A 92 per cent bleeding control rate in this
high risk subgroup of patients who fail to stop bleeding without tamponade equals or
betters that obtained in most centres for ’all comers" with variceal bleeding.
Although only four patients are recorded as having died of uncontrolled bleeding,
there were other deaths recorded as liver failure where further bleeding preceded
organ failure. In this situation where bleeding precedes rather than succeeds liver
failure, perhaps these deaths should also be attributed to bleeding, although this is a
difficult area of definition. We should not lose sight of the fact that oesophageal
tamponade controlled bleeding initially in 99 per cent of patients; this modality still
has an important holding role to play. The tendency to do immediate sclerotherapy
without tamponade is gaining support but it is not always practical or possible if one
believes in early referral of these patients to centres with a special interest in portal
hypertension. The evolution of management in this series over a ten year period is
similar to that of many centres- the abandonment of post-injection tamponade, the
decreasing use of the rigid instrument, the flirtation with sclerosing agents other than
ethanolamine oleate, etc. The problem of how best to manage the patients who
continue bleeding in spite of sclerotherapy remains. Of the 17 patients who
continued to bleed after acute injection sclerotherapy, 13 were subjected to surgery
and five survived. The authors give the impression that perhaps better results could
have been obtained by a more aggressive approach, that is, "Patients not controlled
by one or two injection sclerotherapy treatments should be subjected to more major
surgery, either shunt or transection." However surgery can only help in stopping
bleeding, and in this series only four patients died from bleeding. The majority, 70
per cent of the whole series and 61 per cent of those treated surgically, died of liver
failure where operation has nothing to offer. Indeed the 61 per cent mortality in the
surgical group does not differ greatly from the 71 per cent mortality even after four
injection. The problem is that persistent bleeding often indicates a severe degree of
liver dysfunction and in addition is sometimes the result of post-sclerotherapy
oesophageal ulceration, neither situation being condusive to operation. In addition
it is commonly Child’s Grade C patients who present this problem of recurrent
bleeding and unfortunately few Grade C patients survive emergency surgery.
Oesophageal transection of a recently injected oedematous and possibly ulcerated
oesophagus is hazardous and even shunt surgery does not necessarily stop bleeding
from an oesophageal ulcer overlying a varix. Perhaps there is a place for resorting to
re-insertion of the Sengstaken tube for a few days with intermittent tamponade in
these difficult rebleeders. The number of patients failing with sclerotherapy is so
small that it will be difficult to get a scientific answer to as the best therapy in this
situation.
George W. Johnston
Royal Victoria Hospital
Grosvenor Road
Belfast
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INVITED COMMENTARY
The data presented by Kahn and colleagues summarized a 10 year experience of
sclerotherapy in management of acute variceal bleeding. Since the group at
Capetown first published their work on sclerotherapy in 1979, accumulation of data
from around the world has clearly established the efficacy of the procedure. What is
urgently needed, however, are criteria for determination of failure of sclerotherapy,
without which its true role in the overall management of variceal bleeding remains
undefined. Unlike surgical treatment where the effects are immediate, obliteration
of varices with sclerotherapy takes multiple sessions over time. Should recurrent
bleeding from residual patent varices be called failure of sclerotherapy or inadequate
sclerotherapy?
It seems to this author that there are two possible situations where one may
consider sclerotherapy to be a failure. The first is more clear cut: failure to stop
bleeding with sclerotherapy during an acute episode; and the second is recurrent
hemorrhage during a course of chronic sclerotherapy.
In the series of Kahn et al a single iniection sufficed to control70% of the bleeding
episodes, while in 22% multiple injections were required. In 8% sclerotherapy
simply failed to control bleeding, and in 2.3% the patients died from continued
bleeding. The experience elsewhere, as well as our own, supports the approximation
that 5-10% of all patients bleeding from varices cannot be controlled acutely by
sclerotherapy. The important question, therefore, is why doesn’t sclerotherapywork
in this group of patients?
In the Syracuse series of 53 consecutive patients admitted with bleeding from
esophageal varices and related lesions, five required emergency surgery due to
failure to stop bleeding with sclerotherapy. The factors common to this small group
are: massive ascites (6.3 + 1.5 L), massive blood loss before control (9 +_ 3 Units), a
portal pressure of 27.6 + 6.7 cm H20, and poor liver function (one patient in B and
four patients in C, Pugh-Child’s classification). Conditions such as gastric variceal
bleeding and portal hypertensive gastropathy are unsuitable for sclerotherapy and
are not included in the Kahn series.
In our investigation of the sources of recurrent hemorrhage during chronic
sclerotherapy 1, we found that bleeding most often came from persistently patent
varices, and that eradication of these varices was ultimately achievable in 15 out of
18 patients with continued sclerotherapy. Recurrent bleeding was rare after
eradication. New varices, defined as vessels not seen in previous videorecordings,
occurred in 2 patients and were never the source of bleeding. We feel that recurrent
bleeding from patent varices should not be branded as failiure of sclerotherapy,
particularly in view of the penalty that may be associated with changing to a more
invasive treatment modality. In our view, true failures would include bleeding from
deep ulcerations caused by sclerotherapy and from sources other than esophageal
varices for which sclerotherapy is ineffective.218 D. KAHN, P.C. BORNMAN and J. TERBLANCHE
Kahn and colleagues suggested that surgical treatment should be consideredwhen
sclerotherapy has failed to control acute bleeding. Would such patients fare betters
with surgical treatment? Such an approach would seem reasonable but unfortunately
no data were presented to answer this question. In the Syracuse series, surgical
treatment of patients who continued to bleed after maximal sclerotherapy carries a
mortality of60%, and at a high cost. It may well be that these patients do not respond
well to any form of treatment, irrespective of the degree of invasiveness, but
controlled investigation into options other than surgery, such as combined
radiological, pharmacological and surgical treatment2, would be necessary to
improve the outcome for this difficult group of patients.
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INVITED COMMENTARY
Bleeding oesophageal varices still present a challenge to surgeons and
gastroenterologists and it is good to see that the good initial results of balloon
tamponade and sclerotherapy have been maintained in Capetown, over the last 10
years in a large number of patients. In most people’s experience, about one third of
patients have stopped bleeding when they reach hospital, one third are bleeding
slightly and one third bleeding heavily. Ideally the varices should be injected at the
same time as the diagnostic endoscopy and it is interesting that the authors mention
that they are looking at that area. However, there are still patients in whom the
bleeding is heavy and the endoscopic view is not good enough to allow a safe and
effective injection. The 4 lumen modification of the Sengstaken Blakemore tube is a
safe and effective means of control in experienced hands and it should only be
removed just before sclerotherapy.
The patients in this South African study belong to this difficult group who required
balloon tamponade because they failed to stop bleeding, either spontaneously or
after vasopressin. However, many clinicians do not now consider vasopressin alone,
to be satisfactory and have stopped using it. Metoclopramide and the more
expensive drug, somatostatin, look promising alternatives.
This paper highlights other key problems in the management of bleeding varices.
First, despite a 92% control ofbleeding by sclerotherapy the hospital mortality is still
36% and these patients mainly die of liver failure. The speed of referral to hospital
and the amount of blood lost before the patient reaches expert care may be a factor:
the geography and an efficient referral and transfer systemmay partly account for the
low in-hospital mortality reported by Johnston from Belfast. The other problem is
those patients who continue to bleed and need repeated injection sessions or have toEMERGENCY SCLEROTHERAPY FOR VARICEAL BLEEDING 219
go to emergency surgery. Kahn documents what many have suspected, that the
mortality increases if more than one injection session is needed to control bleeding,
rising to 71% after 4 sessions. At the same time, those few patients (8%) who then
need a transection/devascularisation operation, because bleeding is uncontrolled by
sclerotherapy, also have a high mortality because of their general condition and
because oesophageal oedema or ulceration makes transection difficult or dangerous.
Preventing a rebleed in hospital is as important in reducing the mortality from
bleeding varices as it is from bleeding peptic ulcer. The challenge is to identify these
patients early on and, perhaps, take them straight to surgery, but so far no criteria
have been found. However, in our experience, a number have developed an extra
complication of their cirrhosis such as hepatoma or portal vein thrombosis, and these
conditions are also difficult to diagnose in an emergency.
The best technique of injection is undecided and the Cape Town trial showed equal
results with the rigid endoscope and general anaesthesia or flexible instrument under
sedation. However, occasionally the rigid instrument is more effective in patients
with large varices or those which bleed as soon as the tamponade balloon is deflated.
In patients who are very confused and violent, a general anaesthetic is safer and
makes effective injection easier.
Kahn and colleagues have shown the effectiveness of the tamponade/
sclerotherapy regime; but the answer to preventing and treating bleeding varices in
the future is likely to be pharmacological. The present trend is towards immediate
injection, as soon as bleeding has been controlled by drugs, while balloon tamponade
is reserved for those few who do not repond. Failure of the first injection or
rebleeding while in hospital should be treated quickly and effectively, by surgery if
necessary.
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